GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regado Biosciences Inc (NAS:RGDO) » Definitions » Capex-to-Operating-Income

Regado Biosciences (Regado Biosciences) Capex-to-Operating-Income : 0.00 (As of Jun. 2016)


View and export this data going back to . Start your Free Trial

What is Regado Biosciences Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Regado Biosciences's Capital Expenditure for the three months ended in Jun. 2016 was $0.00 Mil. Its Operating Income for the three months ended in Jun. 2016 was $-12.95 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Regado Biosciences Capex-to-Operating-Income Historical Data

The historical data trend for Regado Biosciences's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regado Biosciences Capex-to-Operating-Income Chart

Regado Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Capex-to-Operating-Income
- - - - -

Regado Biosciences Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regado Biosciences's Capex-to-Operating-Income

For the Biotechnology subindustry, Regado Biosciences's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regado Biosciences's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regado Biosciences's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Regado Biosciences's Capex-to-Operating-Income falls into.



Regado Biosciences Capex-to-Operating-Income Calculation

Regado Biosciences's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2015 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.039) / -52.858
=N/A

Regado Biosciences's Capex-to-Operating-Income for the quarter that ended in Jun. 2016 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -12.95
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regado Biosciences  (NAS:RGDO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Regado Biosciences Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Regado Biosciences's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Regado Biosciences (Regado Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
Executives
Domain Parters Vii L P 10 percent owner ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Associates Domain 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Kim P. Kamdar 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Patrick J Heron director 550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Dp Vii Associates Lp 10 percent owner ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Jeffrey H Cooper director BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Frazier Healthcare V, Lp 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Christopher Peetz officer: Chief Financial Officer C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Andrew J. Fromkin director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Carol L Brosgart director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Regado Biosciences (Regado Biosciences) Headlines

No Headlines